{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:35:16Z","timestamp":1775054116775,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Calcitonin, a neuropeptide, has been shown in preliminary double\u2010blind trials to reduce agitation in patients with acute mania. Given that it has effects similar to those of lithium and anticonvulsants on modulation of second\u2010messenger signaling pathways and stabilization of neuronal membranes, this study examined the efficacy of calcitonin nasal spray in treating acute manic symptoms in patients with treatment\u2010resistant mania using a double\u2010blind, placebo\u2010controlled design.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 46 hospitalized patients experiencing either a manic or a mixed episode, who were refractory to treatment with adequate doses of either a mood stabilizer or an antipsychotic, or a mood stabilizer\/antipsychotic combination, and had a score of \u226516 on the Young Mania Rating Scale (<jats:styled-content style=\"fixed-case\">YMRS<\/jats:styled-content>), were randomized to receive adjunctive nasal calcitonin 200\u00a0IU (n\u00a0=\u00a024) or saline (n\u00a0=\u00a022) spray for three weeks. The primary efficacy measure was the change in <jats:styled-content style=\"fixed-case\">YMRS<\/jats:styled-content> scores using the last observation carried forward (<jats:styled-content style=\"fixed-case\">LOCF<\/jats:styled-content>) method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The clinical and demographic characteristics were similar between the groups. Patients had a mean <jats:styled-content style=\"fixed-case\">YMRS<\/jats:styled-content> score of 26 in the placebo group and a mean score of 25 in the calcitonin group. There were no significant differences in <jats:styled-content style=\"fixed-case\">YMRS<\/jats:styled-content> scores or percentage responders at three weeks between patients who received calcitonin and those who received placebo. There were also no significant differences in change scores on any other scales. Few patients experienced any adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study does not support the use of nasal calcitonin in the treatment of treatment\u2010resistant mania.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bdi.12062","type":"journal-article","created":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T11:28:46Z","timestamp":1364815726000},"page":"359-364","source":"Crossref","is-referenced-by-count":8,"title":["A double\u2010blind, placebo\u2010controlled study of adjunctive calcitonin nasal spray in acute refractory mania"],"prefix":"10.1111","volume":"15","author":[{"given":"Astrid","family":"Vik","sequence":"first","affiliation":[{"name":"Department of Psychiatry University of British Columbia Vancouver BC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Ravindran","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Toronto Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u2010Shin","family":"Shiah","sequence":"additional","affiliation":[{"name":"National Defense Medical Center Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Wong","sequence":"additional","affiliation":[{"name":"School of Population and Public Health University of British Columbia Vancouver BC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazlin","family":"Walji","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of British Columbia Vancouver BC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond W","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of British Columbia Vancouver BC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi N","family":"Yatham","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of British Columbia Vancouver BC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.5.543"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00219.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00672.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2005.01.001"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.1208e34"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.6.759"},{"key":"e_1_2_7_8_1","first-page":"109","article-title":"Calcitonin and bipolar disorder: a hypothesis revisited","volume":"23","author":"Vik A","year":"1998","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1979.01780010078008"},{"key":"e_1_2_7_10_1","first-page":"340","volume-title":"Calcium and calcitonin in bipolar affective disorder","author":"Carman JS","year":"1984"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00308-4"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.1.118"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.4.1.3"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199400940-00009"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.020204.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2008.00636.x"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbdi.12062","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bdi.12062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:59:49Z","timestamp":1697633989000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bdi.12062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/bdi.12062"],"URL":"https:\/\/doi.org\/10.1111\/bdi.12062","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}